Inventories

6 Months Ended

Jun. 30, 2021

Inventories

Inventories

6. Inventories

The Group’s inventory balance of $11,114 and $13,144 as of June 30, 2021 and December 31, 2020, respectively, mainly consisted of finished goods purchased from Tesaro, Inc., now GlaxoSmithKline (GSK), for distribution in Hong Kong, and from NovoCure Limited (“Novocure”) and Deciphera Pharmaceuticals, LLC (“Deciphera”) for distribution in Hong Kong and China, as well as finished goods, work in process and certain raw materials for ZEJULA commercialization in China.

	As of
	June 30, 2021		December 31, 2020
	$		$
Finished goods		4,477		3,041
Raw materials		6,269		10,103
Work in process		368		—
Inventories		11,114		13,144

The Group writes down inventory for any excess or obsolete inventories or when the Group believes that the net realizable value of inventories is less than the carrying value. During the three and six months ended June 30, 2021, the Group recorded write-downs of $277 and $290, respectively, in cost of revenues. During the three months and six months ended June 30, 2020, the Group recorded write-downs of $7 and $7, respectively, in cost of revenues.